Active Ingredient: Bimekizumab
Bimekizumab is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Subcutaneous, 320 milligrams bimekizumab, once every 2 weeks, 5 doses in total. Afterwards, subcutaneous, 320 milligrams bimekizumab, once every 4 weeks.
The recommended dose for adult patients with hidradenitis suppurativa is 320 mg every 2 weeks up to Week 16 and every 4 weeks thereafter.
Consideration should be given to discontinuing treatment in patients who have shown no improvement by 16 weeks of treatment.
Suitable areas for injection include thigh, abdomen and upper arm. Injection sites should be rotated and injections should not be given into psoriasis plaques or areas where the skin is tender, bruised, erythematous, or indurated.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
